Prometheus Biosciences Statistics
Share Statistics
Prometheus Biosciences has 47.81M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 47.81M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 43 |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -31.52 and the forward
PE ratio is null.
Prometheus Biosciences's PEG ratio is
-1.46.
| PE Ratio | -31.52 |
| Forward PE | n/a |
| PS Ratio | 656.18 |
| Forward PS | n/a |
| PB Ratio | 6.61 |
| P/FCF Ratio | -35.47 |
| PEG Ratio | -1.46 |
Financial Ratio HistoryEnterprise Valuation
Prometheus Biosciences has an Enterprise Value (EV) of 4.21B.
| EV / Sales | 617.57 |
| EV / EBITDA | -28.85 |
| EV / EBIT | -34.12 |
| EV / FCF | -33.38 |
Financial Position
The company has a current ratio of 31.04,
with a Debt / Equity ratio of 0.04.
| Current Ratio | 31.04 |
| Quick Ratio | 31.08 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.2 |
| Debt / FCF | -0.23 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -20.97% and Return on Invested Capital is -20.57%.
| Return on Equity | -20.97% |
| Return on Assets | -19.14% |
| Return on Invested Capital | -20.57% |
| Revenue Per Employee | $70,195.88 |
| Profits Per Employee | $-1,461,360.82 |
| Employee Count | 97 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -629K |
| Effective Tax Rate | 0.44% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is -0.49, so Prometheus Biosciences's
price volatility has been lower than the market average.
| Beta | -0.49 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 184.19 |
| 200-Day Moving Average | 109.6 |
| Relative Strength Index (RSI) | 84.04 |
| Average Volume (20 Days) | 1,217,911 |
Income Statement
In the last 12 months, Prometheus Biosciences had revenue of 6.81M
and earned -141.75M
in profits. Earnings per share was -3.49.
| Revenue | 6.81M |
| Gross Profit | 6.81M |
| Operating Income | -145.78M |
| Net Income | -141.75M |
| EBITDA | -145.78M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -3.49 |
Full Income StatementBalance Sheet
The company has 292.42M in cash and 29.54M in
debt, giving a net cash position of 262.88M.
| Cash & Cash Equivalents | 292.42M |
| Total Debt | 29.54M |
| Net Cash | 262.88M |
| Retained Earnings | -331.09M |
| Total Assets | 758.41M |
| Working Capital | 707.06M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -123.25M
and capital expenditures -2.7M, giving a free cash flow of -125.96M.
| Operating Cash Flow | -123.25M |
| Capital Expenditures | -2.7M |
| Free Cash Flow | -125.96M |
| FCF Per Share | -3.1 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -2140.96% and -2081.83%.
| Gross Margin | 100% |
| Operating Margin | -2140.96% |
| Pretax Margin | -2081.83% |
| Profit Margin | -2081.83% |
| EBITDA Margin | -2140.96% |
| EBIT Margin | -2140.96% |
| FCF Margin | -1849.86% |
